Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V406 Port Delivery System for choroidal neovascularization due to age-related macular degeneration
2015-003816-19Phase 2Terminated
- Sponsor
- ForSight VISION4
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of pazopanib in exudative macular degeneration (2 arms), sponsored by ForSight VISION4. Primary endpoint: Ocular and systemic safety of sustained intraocular pazopanib delivery from the V406 PDS Implant. Started Jun 2016; status: terminated.
02
Drugs
pazopanib
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2015-003816-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003816-19.